文献速递甲状腺疾病

rhTSH与左甲状腺素撤退辅助放射性碘治疗甲状腺乳头状癌远处转移的结局比较

Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer.
PubMed 文献 · Thyroid · 2021-07-21

本研究回顾性分析2006至2018年间95例因远处转移接受放射性碘治疗的甲状腺乳头状癌患者,其中27例(28.4%)采用左甲状腺素撤退(LTW)准备,68例(71.6%)采用重组人促甲状腺激素(rhTSH)准备。两组在病灶摄碘能力、无进展生存期和疾病特异性生存期上均无显著差异,rhTSH组唾液腺炎发生率相似,提示rhTSH可作为已知远处转移患者放射性碘治疗的替代准备方式。

要点

  • rhTSH与LTW准备后放射性碘治疗在远处转移性PTC中摄碘能力相似。
  • 两组无进展生存期和疾病特异性生存期无显著差异。
  • rhTSH组唾液腺炎发生率与LTW组相当,安全性良好。

核心结论

  • 两种放射性碘治疗准备方法在摄碘能力和临床反应上无差异。
  • rhTSH可作为已知远处转移患者放射性碘治疗的替代准备方法,临床结局与LTW相似且安全性良好。

研究设计与样本

  • 回顾性分析2006至2018年因远处转移接受放射性碘治疗的甲状腺乳头状癌患者。
  • 共纳入95例患者,27例(28.4%)采用左甲状腺素撤退准备,68例(71.6%)采用rhTSH准备。

主要发现

  • 两组临床病理特征相似,仅rhTSH组诊断时中位年龄更高(p=0.001)。
  • 首次放射性碘治疗远处转移时中位年龄LTW组63岁(IQR 23) vs rhTSH组70岁(IQR 26.75),p=0.06。
  • 两组摄碘能力相似(p=0.973)。
  • 中位无进展生存期(p=0.076)和疾病特异性生存期(p=0.084)在LTW与rhTSH组间相似。
  • 放射性碘治疗相关副作用:唾液腺炎在LTW组1例(3.7%),rhTSH组5例(7.4%),p=0.670。

临床怎么用

  • 对于已知远处转移的甲状腺乳头状癌患者,可考虑使用rhTSH作为放射性碘治疗的替代准备方法。

局限性

  • 回顾性研究设计。
  • 样本量有限(95例)。
  • rhTSH尚未被FDA或EMA批准用于远处转移性PTC的放射性碘治疗准备。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Thyrotropin alfa (rhTSH) is not currently approved by the Food and Drug Administration or European Medicines Agency for the preparation of radioactive iodine therapy (RAIT) in patients with distant metastatic papillary thyroid cancer (PTC). There are only a few studies comparing rhTSH with levothyroxine withdrawal (LTW) in this context. Our main aim was to compare the two methods of RAIT preparation in terms of avidity and structural/biochemical response in distant metastatic PTC. We also intended to evaluate whether the two methods of RAIT preparation represented independent prognostic factors for progression-free survival (PFS) and disease-specific survival (DSS) in this subset of patients. Methods: We performed a retrospective analysis of all patients with PTC treated with RAIT for distant metastatic disease between 2006 and 2018. We included 95 PTC patients-27 (28.4%) had LTW and 68 (71.6%) had rhTSH for RAIT. Results: The two groups presented similar clinicopathological characteristics, except for median age at PTC diagnosis, which was higher in the rhTSH group (p = 0.001), but the median age at first RAIT for distant metastatic disease was not different between the two methods of preparation, 63 years old (interquartile range [IQR] 23) in the LTW group versus 70 (IQR 26.75), p = 0.06. Avidity was similar between the two groups (p = 0.973). Median estimate PFS (p = 0.076) and DSS (p = 0.084) were also similar between LTW and rhTSH. Regarding RAIT-related side effects, only 1 (3.7%) patient and 5 (7.4%) patients in the LTW and rhTSH groups, respectively, reported sialadenitis (p = 0.670). Conclusions: There were no differences between the two methods of RAIT preparation regarding avidity and clinical response. rhTSH may be used as an alternative method of preparation for RAIT in patients with known distant lesions, as it presents similar clinical outcomes to LTW and a good safety profile.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Simões-Pereira J, Ferreira TC, Limbert E, et al. Outcomes of Thyrotropin Alfa Versus Levothyroxine Withdrawal-Aided Radioiodine Therapy for Distant Metastasis of Papillary Thyroid Cancer. Thyroid. 2021. PMID: 34155923. doi:10.1089/thy.2021.0013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。